Modulation of paracetamol antinociception by caffeine and by selective adenosine A(2) receptor antagonists in mice
Godfrey, L, Yan, L, Clarke, GD, Ledent, C, Kitchen, I and Hourani, SMO (2006) Modulation of paracetamol antinociception by caffeine and by selective adenosine A(2) receptor antagonists in mice EUR J PHARMACOL, 531 (1-3). pp. 80-86.
Available under License : See the attached licence file.
This study investigated the involvement of adenosine receptors in the interaction between paracetamol and caffeine in mice, using the adenosine A2A receptor antagonist 5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (SCH58261) and the adenosine A2B receptor antagonist 1-propyl-8-p-sulfophenylxanthine (PSB1115), in the tail immersion and hot-plate tests. Paracetamol (10–200 mg/kg) was antinociceptive in both tests, but, in contrast to previous studies, caffeine (10 mg/kg) was pronociceptive in the tail immersion test, and reduced the effects of paracetamol in both tests. SCH58261 (3 mg/kg) was antinociceptive in both tests and in its presence paracetamol (50 mg/kg) had no further effect. PSB1115 (10 mg/kg) had little effect alone but potentiated the effect of paracetamol (50 mg/kg) in the hot-plate test and abolished it in the tail immersion test. These results suggest that adenosine A2B receptors may be involved in the action of paracetamol in a pathway-dependent manner, and also support the existence of pronociceptive adenosine A2A receptors
|Divisions :||Faculty of Health and Medical Sciences > Biochemistry and Physiology|
|Date :||15 February 2006|
|Identification Number :||10.1016/j.ejphar.2005.12.004|
|Uncontrolled Keywords :||adenosine antagonist, paracetamol, caffeine, antinociception, adenosine A(2A) receptor knockout mice, RAT-BRAIN, A(1) RECEPTOR, LACKING, PAIN, ACETAMINOPHEN, PHARMACOLOGY, HEPATOTOXICITY, MECHANISMS, DEFICIENT, ANALGESIA|
|Additional Information :||Copyright © 2006 Elsevier B.V. All rights reserved. NOTICE: this is the author’s version of a work that was accepted for publication in European Journal of Pharmacology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in European Journal of Pharmacology, 531(1-3), February 2006, DOI:10.1016/j.ejphar.2005.12.004|
|Depositing User :||Symplectic Elements|
|Date Deposited :||07 Mar 2012 16:29|
|Last Modified :||23 Sep 2013 19:06|
Actions (login required)
Downloads per month over past year